MedTrace Logo

Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis

NCT06269185 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 271

Last updated 2024-10-28

No results posted yet for this study

Summary

Anti-TNF (tumor necrosing factor) treatment with infliximab (IFX) and adalimumab (ADA) are established first-line biological therapies used in treatment of patients with ulcerative colitis (UC). There are no head-to-head comparative studies between these two drug but meta-analysis of randomized controlled trials states that IFX might be more effective than ADA for the induction of clinical remission. However, several observational studies conclude that ADA seem to have similar effect as IFX in treating patients with UC but these studies have limitations.

The overall aim of this retrospective multicenter observational cohort study is to evaluate if there is a difference in efficacy between infliximab (IFX) and adalimumab (ADA) in treating bio-naive patients with UC in the short and long term during the modern era when therapeutic drug monitoring have been used to optimize anti-TNF treatment.

Conditions

Interventions

DRUG

Infliximab

Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis

DRUG

Adalimumab

Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Principal Investigators

  • Börje Jonefjäll, PhD · Sahlgrenska University Hospital / Mölndal

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-06
Primary Completion
2024-10-18
Completion
2024-10-18
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06269185 on ClinicalTrials.gov